Try GOLD - Free

China's Innovative Approach to Universal Health Coverage

BioSpectrum Asia

|

BioSpectrum Asia August 2025

China has successfully implemented various medical insurance reforms and development tasks under five principles including promoting equity and accessibility, the rule of law, technological empowerment, coordinated development and safeguarding the security of the fund during the first four years of the 14th Five-Year Plan (the 2021-2025 period).

The authorities nationwide have spent about 72.3 billion yuan (about $10.1 billion) to assist people from disadvantaged groups, providing support for 350 million instances of insurance coverage. China's basic medical insurance has maintained a coverage rate of around 95 per cent, with over 1.32 billion people enrolled in 2024. Medical assistance schemes cover approximately 80 million people in China each year, helping to ensure that they can benefit from the insurance programme.

From 2021 to 2024, nearly 20 billion medical visits received medical insurance reimbursement, a 1.6-fold increase from 2020. As of June 2025, 253 million people had participated in maternity insurance, with cumulative fund expenditures of 438.3 billion yuan and 96.1432 million benefits received. China has also optimised the "one-stop birth" process, allowing newborns to enroll in insurance with just a birth certificate. Thirty-one provinces and the Xinjiang Production and Construction Corps have included assisted reproductive services in medical insurance reimbursement. Nearly 60 per cent of coordinated regions nationwide provide direct maternity benefits to insured female employees.

MORE STORIES FROM BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Collaborative R&D: Partnerships shaping the future of biopharma

Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.

time to read

2 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Quantum Computing: Future of diagnostics is being coded today

A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.

time to read

4 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

First Pacific woman to serve as public health director in NZ

The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Hugel launches botulinum toxin Letybo in Malaysia

South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Australia designs smart wound monitor to improve chronic infection care

Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Revvity unveils innovative reagent technology to accelerate therapeutics development

US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B

Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education

HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI

Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.

time to read

1 min

BioSpectrum Asia Sep 2025

Listen

Translate

Share

-
+

Change font size